Refine by
Biobank Articles & Analysis
18 articles found
Many oncology drugs have been abandoned by pharmaceutical companies due to poor performance in phase I, II, or III clinical trials. These drugs represent untapped potential treatments for indications outside of those initially investigated. With research and development costs for a single new drug estimated between $2–3 billion, abandoned drugs represent an opportunity to bring drugs to ...
The Predictive Oncology machine learning approach paired with our proprietary biobank of frozen dissociated tumor cells (DTCs) offers a screening opportunity for many repurposing candidates to be assessed, with outputs from this effort reflective of both confident predictions (Machine Learning) and wet lab ...
In this white paper, Predictive Oncology (POAI) highlights a recent successful project in partnership with the University of Michigan Natural Products Discovery Core (NPDC) through the ACE program. The ACE program supports academic researchers in their early drug discovery and development initiatives by providing access to the POAI proprietary active machine learning platform and ...
· Stable and Scalable Systems – The ability to cryopreserve organoids in biobanks and expand them indefinitely arises from their self-renewal capabilities, stem cell differentiation, and inherent self-organization, resulting in a reliable and consistent research model. ...
What is a Biorepository? A biorepository, or "biobank", is a specialized facility designed to store, archive, and distribute biological samples for research or clinical purposes. ...
This can be for donations, to store reproductive samples to delay childbearing or for individuals undergoing gonadotoxic treatments who may wish to have children. Biobanks: Biobanks are becoming more common in healthcare and pharmaceutical research. ...
“New technological components to allow interoperability and data analysis in biobanks” Call: EUROSTARS-2 (International Intercompany Action) Reference No.: ...
Others are tapping into public datasets, such as the Cancer Genome Atlas or UK Biobank, and finding ways to mine those data for specific applications. ...
Federation will play a crucial role in enabling the future possibility to collaborate with international partners such as Genomics England, France Genomique, Genomic Medicine Sweden and other biobanks from around the world. Virtually connecting these sensitive datasets, enabling joint analysis that is however performed in situ without moving data, can lead to exponentially higher ...
ByLifebit
This requires large databases or biobanks of matched clinical and genomic data, collected and managed by data custodians. ...
ByLifebit
Pharmaceutical companies recognize the growing value of genome data, partnering with biobanks to power massive sequencing projects such as AstraZeneca’s 2 Million Genomes Project and Boehringer Ingelheim joining a nation-wide research collaboration in Finland to analyse 500K genomes. ...
ByLifebit
The phenotype or physiological characteristics exhibited by this individual were nearly identical to those of mice without MC3R. Using data from the UK Biobank and the Children's Longitudinal Study, the team analyzed the phenotype of a copy of the MC3R-encoding gene mutated in volunteers. ...
One of the unique advantages that Altis has is a biobank of cells sourced from organ donors. We have generated a biobank of intestinal epithelial stem cells from multiple donors, with cells from each donor individually isolated from the six regions of the whole intestine (duodenum, jejunum, ileum, ascending colon, transverse colon, and descending colon). This ...
With access to a donor-derived cell biobank and the ability to recapitulate region-specific environments of the intestine, Altis Biosystems is working toward the development of an in vitro RepliGut® model to accurately recapitulate the complex intestinal inflammatory microenvironments. ...
Our current foci are threefold: first, to expand our possible tissue variety, creating a biobank of donor stem cells from individuals with intestinal related diseases; second, replication of the anaerobic conditions of the intestinal lumen; and, finally, to pursue a model that recapitulates the intestinal mucous layer. ...
The statistical power of these models will only increase as we expand our donor biobanks and add samples from more individuals representing a wider range of demographics. ...
To that end, Altis is developing a gut biobank comprised of intestinal and colonic epithelial stem cells from six regions that carry out different functions. ...
Biobanks have become one of the core resources for biomedical research. ...